Etienne Khoury

Etienne Khoury

Auto-generated profile, based on publicly available information

Etienne Khoury

Lipidology Unit, Community Genomic Medicine Center, Department of Medicine, Université de Montréal and ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
EKEtienne Khoury
Etienne Khoury
ALAlex Lauzière
Alex Lauzière
FRFrederick J Raal
Frederick J Raal
JMJohn Mancini
John Mancini
DGDaniel Gaudet
Daniel Gaudet
Background: Homozygous familial hypercholesterolaemia (HoFH) is a rare and life-threatening genetic disease characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels, important xanthomatosis and increased risk of premature atherosclerotic cardiovascular disease. Management of HoFH at an early stage is recommended but conventional lipid-lowering therapies (LLTs) dependent on the LDL-receptor for clearance of LDL particles, are usually not sufficient. However, agents acting independently of the LDL-receptor, such as inhibitors of microsomal triglyceride transfer protein (MTP) or angiopoietin-like protein 3 (ANGPTL3), administered in combination, on top of standard-of-care LLT constitute a promising therapy for HoFH. Case summary: The present case describes a long-term (>10 years) follow-up of a 52-year-old woman with severe HoFH, who was treated with conventional lipid-lowering medications (i.e. statins and ezetimibe) for several years before experiencing the risks and benefits that were encountered with the use of LDL-receptor-independent agents (MTP and ANGPTL3 inhibitors). This combination therapy demonstrated a good long-term safety and efficacy profile, while continuous monitoring of hepatic enzymes (sometimes requiring dose adjustments) and fat accumulation is recommended when using lomitapide. Discussion: Treating this HoFH patient with an LLT involving the combination of MTP and ANGPTL3 LDL-receptor-independent inhibitors (lomitapide and evinacumab, respectively) showed remarkable improvement in LDL-C levels, disappearance of xanthomatosis and regression in atherosclerotic plaques. In addition to safety and efficacy, one should question the affordability and access hurdle that emerging combination of expensive therapies might constitute in the future for the payers. These challenges could eventually limit the clinical use of those innovative treatments despite their clinical benefit.

26 April 2022 in Future Cardiology
Verified
Journal Article
Closed access
EKEtienne Khoury
Etienne Khoury
LCLaurent Croteau
Laurent Croteau
ALAlex Lauzière
Alex Lauzière
DGDaniel Gaudet
Daniel Gaudet
Homozygous familial hypercholesterolemia (HoFH) is a life-threatening disease characterized by extremely elevated LDL cholesterol (LDL-C) levels which result in premature atherosclerotic cardiovasc... Plain language summary Homozygous familial hypercholesterolemia (HoFH) is a life-threatening rare genetic disorder characterized by extremely elevated ‘bad’ cholesterol and resulting in heart disea...

25 April 2024 in Future Cardiology
Verified
Journal Article
Closed access
APAgnieszka Pawlos
Agnieszka Pawlos
EKEtienne Khoury
Etienne Khoury
DGDaniel Gaudet
Daniel Gaudet
Refractory hypercholesterolemia (RH) is characterized by the failure of patients to achieve therapeutic targets for low-density lipoprotein-cholesterol (LDL-C) despite receiving maximal tolerable doses of standard lipid-lowering treatments. It predominantly impacts individuals with familial hypercholesterolemia (FH), thereby elevating the risk of cardiovascular complications. The prevalence of RH is now recognized to be substantially greater than previously thought. This review provides a comprehensive insight into current and emerging therapies for RH patients, including groundbreaking genetic-based therapeutic approaches. The review places emphasis on the dependency of therapies on low-density lipoprotein receptors (LDLRs) and highlights the critical role of considering LDLR activity in RH patients for individualization of the treatment. Refractory hypercholesterolemia (RH) is a condition where patients are unable to get below target levels of 'bad' cholesterol despite receiving maximum doses of standard treatments. It is commonly present in those with a genetic disorder, called familial hypercholesterolemia (FH), known to increase the risk of heart complications. RH's prevalence is now understood to be higher than previously believed and this review offers insights into current and emerging therapies for RH, including genetic-based treatments. It stresses the importance of the mechanistic pathways behind cholesterol clearance, particularly low-density lipoprotein receptor (LDLR) activity, in RH treatment customization. Article highlightsRefractory hypercholesterolemia - definition, epidemiological data.Therapeutic targets for the treatment of refractory hypercholesterolemiaLow-density lipoprotein receptor (LDLR)-dependent therapies targeting cholesterol production and upregulating LDLRThe efficacy of lipid-lowering treatments that depend on low-density lipoprotein receptor (LDLR) activity may be limited in patients with importantly reduced LDLR function, particularly among homozygous familial hypercholesterolemia (HoFH) patients with very low or no residual LDLR activity.3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) inhibitors (statins)Statins as first-line lipid-lowering drugs, mechanism, efficacy, side effects.Adenosine triphosphate (ATP)-citrate lyase inhibitorBempedoic acid is a good therapeutic option for statin-intolerant patients. Mechanism of action, efficacy, side effects.PCSK9 inhibitorsReview of therapeutic options aimed at PCSK9 inhibition including monoclonal antibodies, siRNA, and therapeutic genome editing.LDLR gene replacement therapy and gene editing strategiesClinical trial of LDLR gene replacement therapy in HoFH, potential of clustered regularly interspaced short palindromic repeats (CRISPR)-based methods.LDLR-independent therapiesAngiopoietin-like 3 inhibitionAngiopoietin-like 3 (ANGPTL3) inhibition as a therapeutic target which is LDLR independent. Efficacy of monoclonal antibodies, siRNA, and therapeutic genome editing.MTP inhibitionMechanism of action, efficacy, and side effects of lomitapide.CETP inhibitionDrug development history, efficacy, and limitations of use.Inhibition of apolipoprotein B (apoB) formationMechanism of action, efficacy, and side effects leading to Mipomersen cessation.Cholesterol absorption inhibition: ezetimibeMechanism of action, efficacy, and side effects of ezetimibe.Agents targeting Lipoprotein (a) (Lp[a])Atherogenic mechanisms of Lipoprotein (a) (Lp[a]). Lp(a) lowering the potential of currently available drugs. Novel therapies aimed at Lp(a) reduction are available within clinical trials.Combination of therapiesSummary of lipid-lowering potential of drug combinations.LDL and Lp(a) apheresisTypes of aphereses, indications, limitations of use.High-density lipoprotein (HDL) autotransfusionThe efficacy of plasma delipidation system (PDS-2TM) in patients with atherosclerosis, who do not respond adequately to available pharmacological options.Refractory hypercholesterolemia beyond LDL-cholesterol: residual cardiovascular risk associated with remnant cholesterolThe role of remnant cholesterol in triglyceride-rich lipoproteins in residual cardiovascular risk and potential therapeutic role of anti-apolipoprotein C-III (APOC3) therapy.Refractory hypercholesterolemia in the pediatric populationSummary of available therapeutic options for pediatric population with severe hypercholesterolemia.ConclusionRefractory hypercholesterolemia appears to be a more prevalent condition than might be initially perceived. In terms of its management, it is of particular importance to custom-tailor the appropriate treatment regimen depending on the underlying etiology. The principal determinant for therapy selection should be based on LDL receptor activity.